SPA | Jotup

Global LNG Market Poised for Growth, Aiding Environmental Goals and Energy Needs - ResearchAndMarkets.com

Retrieved on:

Monday, November 13, 2023

The development of LNG import infrastructure, such as regasification terminals and distribution networks, has facilitated global access to LNG.

Key Points:

The development of LNG import infrastructure, such as regasification terminals and distribution networks, has facilitated global access to LNG.
Growing demand for cleaner energy sources, particularly in Asia, incentivizes higher LNG production to meet energy needs and emissions reduction goals.
Import and Export: Japan dominates the global LNG import market, while Australia leads in LNG exports.
Additionally, long-term LNG supply contracts play a crucial role in the LNG market, providing stability and predictability for both buyers and sellers.

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Retrieved on:

Thursday, November 9, 2023

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2023, and provided clinical development and operational highlights.

Key Points:

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2023, and provided clinical development and operational highlights.
“In the third quarter we made meaningful progress across our portfolio,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
The Company received written agreement from the FDA under an SPA for the overall design of the CoMpass trial.
Positive updated Phase 2 data evaluating SC administration of bel-sar for the first-line treatment of adult patients with early-stage CM was presented at AAO 2023.

THE NAMM FOUNDATION ANNOUNCES $477,500 IN GRANTS TO 24 MUSIC-MAKING PROGRAMS

Retrieved on:

Tuesday, December 12, 2023

CARLSBAD, Calif., Dec. 12, 2023 /PRNewswire/ -- The NAMM Foundation continues its vision of creating a more musical world, by providing financial grants to community music-making organizations that are serving as models for outreach and opportunities to make music. In line with the season of celebration and giving, a total of $477,500 has been awarded to 24 music organizations from around the world. The annual grants from NAMM Foundation reflect the generosity of all NAMM members and private donors and their ongoing support for the industry's annual gathering at The NAMM Show.

Key Points:

The annual grants from NAMM Foundation reflect the generosity of all NAMM members and private donors and their ongoing support for the industry's annual gathering at The NAMM Show.
The Mr. Holland's Opus Foundation - NAMM Foundation funding supports the "School Instrument Donation" program serving low-income and under-resourced school music programs in both rural and urban communities across the country.
NAMM Foundation funding supports emerging programs at four existing sites and the addition of a new site.
Young Audiences Arts for Learning - NAMM Foundation funding supports, sustains, and expands the curation and management of The NAMM Foundation " Nonprofit Management Institute " at The 2024 NAMM Show.

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Retrieved on:

Thursday, December 7, 2023

Food, ALS, Patient, Element, FDA, Brainstorm, Marketing, Documentation, Therapy, SPA, Pharmaceutical industry

NEW YORK, Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).

Key Points:

NEW YORK, Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) to discuss NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).
The primary objective of the meeting was to discuss key considerations for a Special Protocol Assessment (SPA) for a planned Phase 3b registrational trial for NurOwn.
As an outcome of the meeting, BrainStorm will submit relevant documentation as outlined by the FDA to support the SPA.
"Our meeting with the FDA provided us with valuable input on the Phase 3b trial design, outlining clear steps forward," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.

Cummins Arabia and Sullivan Palatek Form Strategic Alliance to Distribute Portable Air Compressors in the UAE

Retrieved on:

Tuesday, December 5, 2023

Equipment rental, Fossil fuel, Oil, Arctic Spas, SPA, Partnership, Drug

DUBAI, UAE, Dec. 5, 2023 /PRNewswire/ -- In a strategic move that promises to reshape the landscape of air compressor market in the UAE, Cummins Arabia has joined forces with Sullivan Palatek Asia (SPA).

Key Points:

DUBAI, UAE, Dec. 5, 2023 /PRNewswire/ -- In a strategic move that promises to reshape the landscape of air compressor market in the UAE, Cummins Arabia has joined forces with Sullivan Palatek Asia (SPA).
This alliance introduces SPA's Diesel Driven Portable Air Compressors to the UAE market, under the exclusive distribution of Cummins Arabia.
Sullivan Palatek, with a rich legacy in the compressor industry, mirrors Cummins' ethos of dependability and innovation.
With a majority of Sullivan Palatek's range powered by Cummins engines, Cummins Arabia's well-established network and technical capabilities offer unmatched support in the field.

Cummins Arabia and Sullivan Palatek Form Strategic Alliance to Distribute Portable Air Compressors in the UAE

Retrieved on:

Tuesday, December 5, 2023

Equipment rental, Fossil fuel, Oil, Arctic Spas, SPA, Partnership, Drug

DUBAI, UAE, Dec. 5, 2023 /PRNewswire/ -- In a strategic move that promises to reshape the landscape of air compressor market in the UAE, Cummins Arabia has joined forces with Sullivan Palatek Asia (SPA).

Key Points:

DUBAI, UAE, Dec. 5, 2023 /PRNewswire/ -- In a strategic move that promises to reshape the landscape of air compressor market in the UAE, Cummins Arabia has joined forces with Sullivan Palatek Asia (SPA).
This alliance introduces SPA's Diesel Driven Portable Air Compressors to the UAE market, under the exclusive distribution of Cummins Arabia.
Sullivan Palatek, with a rich legacy in the compressor industry, mirrors Cummins' ethos of dependability and innovation.
With a majority of Sullivan Palatek's range powered by Cummins engines, Cummins Arabia's well-established network and technical capabilities offer unmatched support in the field.

Creating good, middle-class jobs, and building a strong, secure future with European partners

Retrieved on:

Friday, November 24, 2023

Canada and the European Union have long shared a commitment to building strong economies that work for the middle class while standing together to address the challenges our world faces.

Key Points:

Canada and the European Union have long shared a commitment to building strong economies that work for the middle class while standing together to address the challenges our world faces.
With increased European demand for clean energy, getting even more Canadian resources like critical minerals and hydrogen to European markets will continue to create jobs and growth for Canadians.
At the Summit, the Prime Minister highlighted important progress on Canadian hydrogen exports bound for European markets.
At the Summit, the Prime Minister welcomed the European Union as the newest partner in the Global Carbon Pricing Challenge .

BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS

Retrieved on:

Monday, November 20, 2023

Brainstorm, ALS, US Foods, FDA, Marketing, Therapy, US FDA, SPA, Biologics license application, Pharmaceutical industry, Agency

NEW YORK, Nov. 20, 2023 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the US Food & Drug Administration (US FDA) has granted the company a meeting to discuss the regulatory path forward for NurOwn® in amyotrophic lateral sclerosis (ALS). The meeting is scheduled to take place on December 6, 2023. Brainstorm will discuss plans for a Special Protocol Assessment (SPA) with the FDA to agree on the overall protocol design for a confirmatory Phase 3 trial in ALS.

Key Points:

The meeting is scheduled to take place on December 6, 2023.
Brainstorm will discuss plans for a Special Protocol Assessment (SPA) with the FDA to agree on the overall protocol design for a confirmatory Phase 3 trial in ALS.
"We are pleased that the FDA has granted this expedited in-person meeting to discuss the best path forward for NurOwn for ALS," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.
"Our proposed plan is to conduct a confirmatory Phase 3b trial and it is important that we are aligned with the Agency on the expected requirements for re-submitting a Biologics License Application.

Emeren Group and Eiffel Investment Group's Joint Venture Signs an Agreement to Sell 29 MWp Solar Portfolio in Spain

Retrieved on:

Tuesday, November 14, 2023

NYSE, Municipality, SPA, Partnership, JV, Electricity, Machelones, PV, Environment, Optimism, Renewable energy

The 29 MWp portfolio comprises three late-stage projects located in the Municipality of Algorfa, Alicante, Spain, in an advanced phase of obtaining the Administrative Authorisation for Construction (the "AAC").

Key Points:

The 29 MWp portfolio comprises three late-stage projects located in the Municipality of Algorfa, Alicante, Spain, in an advanced phase of obtaining the Administrative Authorisation for Construction (the "AAC").
Yumin Liu, CEO of Emeren Group, said, "We're delighted to announce the signing of these three utility-scale projects in Spain.
Our partnership with Eiffel Investment Group not only strengthens our presence in Spain but also aligns seamlessly with our strategic expansion across Europe.
Advisors involved in this transaction include financial advisory from Finergreen, legal counsel provided by Squire Patton Boggs, and technical support from Everoze for Emeren Group and Eiffel Investment Group.

Third time at CIIE, Perfect Diary's parent company marching on the road of science and technology

Retrieved on:

Thursday, November 9, 2023

SHANGHAI, Nov. 9, 2023 /PRNewswire/ -- This year, Yatsen Group, the parent company of Perfect Diary, joined the Expo with the theme "A Beauty Discovery Journey Powered by Technology" and announced the layout of "Yatsen's Road of Science and Technology" on the spot, aiming to empower the Group's brands including Perfect Diary with its independent innovation and R&D strategy. In addition, Galénic, a high-end skincare brand of Yatsen Group that has been a pioneer in scientific skincare for 45 years, and EVE LOM, luxury healing skincare legend, brought their latest R&D achievements and cutting-edge products to the Expo, and took advantage of the vast stage to show Yatsen Group's continuous commitment to R&D and its roadmap of development both at home and abroad.

Key Points:

One global leading cosmetic factory, Perfect Diary initiated "Integrated Research of Both Makeup and Skincare"
At this year's Expo, Huang Jinfeng released the strategic layout of "Yatsen's Road of Science and Technology"for the first time.
He said: "The national policy promotes independent innovation and quality development of the beauty industry.
Yatsen Group has ridden on the tides of policies and trends, and is committed to becoming a beauty enterprise of new technology, boasting brand development driven by science, technology and intellectual creation.
On this international stage, Yatsen Group once again presented the new R&D breakthroughs and black technology products from two high-end skincare brands, Galénic and EVE LOM.